FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

ADMA Biologics, Inc. ADMA

Mixed   broader-coverage candidate · ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from bloo

On FrontierLab's discovery record since 2026-07-16 (11 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-10-03), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)8%
Gross margin64.7%
Gross profits / assets0.48
Rule of 4050.3
Net margin42.3%
Cash runway (months)—
PEG—
Price / sales4.4

Quality checklist

Fundamentals — snapshot as of 2026-10-03

StageEstablished
Share issuance (YoY)-7.3% · buying back shares
Moat—
TAM—
P/E (trailing)13.9
EPS (trailing)$0.70
Burn multiple—
Gross-margin trend (pts)11.7
Cash / assets0.2
Net debt / EBITDA0.3
Statements as ofQ2 FY2026 · filed 2026-08-05

Momentum context — a snapshot from 2026-10-03, not current

Price at surface$9.72 (as of 2026-10-03)
52-week range$7.21 – $20.46
% off 52-wk high-52.5%
RSI (14)53
Relative volume0.9×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-10-03 (end-of-day). How grades are computed →